Wells Fargo
DSGN icon

Wells Fargo’s Design Therapeutics DSGN Stock Holding History

Wells Fargo’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$406K Buy
28,072
+19,045
+211% +$237K ﹤0.01% 4767
2026
Q1 		$96K Sell
9,027
-17,759
-66% -$180K ﹤0.01% 5123
2025
Q4 		$251K Buy
26,786
+8,469
+46% +$66.3K ﹤0.01% 4938
2025
Q3 		$138K Sell
18,317
-1,967
-10% -$9.85K ﹤0.01% 5143
2025
Q2 		$68.4K Buy
20,284
+1,438
+8% +$5.38K ﹤0.01% 5399
2025
Q1 		$72.7K Buy
18,846
+418
+2% +$1.99K ﹤0.01% 5255
2024
Q4 		$114K Buy
18,428
+4,013
+28% +$23.2K ﹤0.01% 5131
2024
Q3 		$77.6K Buy
14,415
+618
+4% +$2.91K ﹤0.01% 5159
2024
Q2 		$46.2K Buy
13,797
+2,291
+20% +$8.93K ﹤0.01% 5323
2024
Q1 		$46.4K Buy
11,506
+1,484
+15% +$3.96K ﹤0.01% 5283
2023
Q4 		$26.6K Buy
10,022
+1,990
+25% +$4.56K ﹤0.01% 5533
2023
Q3 		$19K Sell
8,032
-4,431
-36% -$20.7K ﹤0.01% 5622
2023
Q2 		$78.5K Buy
12,463
+6,469
+108% +$39.6K ﹤0.01% 5180
2023
Q1 		$34.6K Buy
+5,994
New +$44.8K ﹤0.01% 5368
2022
Q4 		– Sell
-406
Closed -$7K – 7518
2022
Q3 		$7K Sell
406
-30
-7% -$597 ﹤0.01% 5805
2022
Q2 		$6K Sell
436
-217
-33% -$2.93K ﹤0.01% 5939
2022
Q1 		$10K Sell
653
-9,290
-93% -$142K ﹤0.01% 6259
2021
Q4 		$213K Buy
+9,943
New +$171K ﹤0.01% 5226

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wells Fargo's DSGN Position: Q2 2026 in Review

Wells Fargo increased its Design Therapeutics (DSGN) stake by 211% in Q2 2026, buying an estimated $237K and bringing the position to 28,072 shares worth $406K. The position accounts for ﹤0.01% of the portfolio, ranked #4767.

Wells Fargo first reported a position in DSGN in Q4 2021 and has held it in 18 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Wells Fargo held 28,072 shares of Design Therapeutics worth $406K as of Q2 2026.
  • Wells Fargo bought 19,045 Design Therapeutics shares in Q2 2026, an estimated $237K.
  • Design Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4767 holding.
  • Wells Fargo first reported a position in Design Therapeutics in Q4 2021 and has held it in 18 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.